Immunisation schedule of the Pediatric Spanish Association: 2024 recommendations by Francisco José Álvarez García, Antonio Iofrío de Arce, Javier Álvarez Aldeán, Elisa Garrote Llanos, Lucía López Granados, María Luisa Navarro Gómez, Valentín Pineda Solas, Irene Rivero Calle, Jesús Ruiz-Contreras, Ignacio Salamanca de la Cueva, Pepe Serrano Marchuet, Francisco José Álvarez García, Antonio Iofrío de Arce, Javier Álvarez Aldeán, María Garcés-Sánchez, Elisa Garrote Llanos, Abián Montesdeoca Melián, María Luisa Navarro Gómez, Valentín Pineda Solas, Irene Rivero Calle, Jesús Ruiz-Contreras, Pepe Serrano Marchuet

“…The AEP 2025 Vaccination and Immunization Schedule recommended for children, adolescents and pregnant women residing in Spain features the following novelties:Due to the increase in measles cases and outbreaks in recent years, we recommend advancing the second dose of measles, mumps and rubella (MMR) vaccine to 2 years of age.As a consequence of the above, since many autonomous communities (ACs) use the quadrivalent vaccine for the second dose of MMR and varicella vaccines, we recommend, for all ACs, advancing the second dose of varicella vaccine to 2 years of age.Due to the very significant increase in cases of pertussis since late 2023 and especially in 2024, we recommend advancing the dose of Tdap given in adolescence to 10–12 years of age.To complete protection against meningococcal disease in adolescence, we recommend vaccination against MenB at age 12 years.We believe that vaccination against seasonal influenza should be routine up to age 18 years, but given the disappointing coverage in children aged 6–59 months, we currently consider that improving this coverage should be prioritised, extending vaccination to children and adolescents aged 5–18 years once this objective has been achieved.Among other aspects, the routine immunization tables for healthy individuals and risk groups, the use of the new extended-valence conjugate vaccines against pneumococcal disease, routine vaccination at 4 months of age with MenACWY and vaccination against SARS-CoV-2 for individuals aged more than 6 months with risk factors remain unchanged with respect to the 2024 schedule. …”
Get full text

Safety and effects of anti-obesity medications on weight loss, cardiometabolic, and psychological outcomes in people living with overweight or obesity: a systematic review and meta... by Leiling Liu, Zhiqi Li, Wenrui Ye, Pu Peng, Yurong Wang, Luqing Wan, Jiangnan Li, Mei Zhang, Yihua Wang, Runqi Liu, Danyan Xu, Jingjing Zhang

“…Considering cardiometabolic risk factors, tirzepatide shows the best blood pressure- and glucose-lowering benefits, while semaglutide and liraglutide reduce the risk of MACEs. …”
Get full text

COVID-19 – if the cure is worse than the disease. The Italian chaos by Giuseppe FERRARI

“…It is clear that although also young people can be severely infected by the virus, the mortality rate is higher among the elderly and often worsen by risk factors like hypertension and obesity. Looking at these evidences it is astonishing that the task force advising the Italian Government has not studied specific restrictive rules for age groups more at risk. …”

Selected Abstracts of the 20th International Workshop on Neonatology and Pediatrics; Cagliari (Italy); October 23-26, 2024 by --- Various Authors

“…Vendemmia (Aversa and Naples, Italy) ABS 18. RISK FACTORS FOR RECOARCTATION OF THE AORTA AFTER SURGICAL REPAIR IN PEDIATRIC PATIENTS • G. …”
Get full text